ABT - Abbott Laboratories
| Previous Close | 90.73 |
| Open | 90.85 |
| Bid | 90.09 x 900 |
| Ask | 90.55 x 1100 |
| Day's Range | 90.21 - 91.53 |
| 52 Week Range | 68.80 - 92.45 |
| Volume | 4,056,617 |
| Avg. Volume | 4,830,467 |
| Market Cap | 159.869B |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | 49.13 |
| EPS (TTM) | 1.84 |
| Earnings Date | Apr 14, 2020 - Apr 19, 2020 |
| Forward Dividend & Yield | 1.44 (1.59%) |
| Ex-Dividend Date | Jan 13, 2020 |
| 1y Target Est | 100.15 |
- PR Newswire
Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson's Disease
Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication for the company's Infinity™ Deep Brain Stimulation (DBS) system to include targeting of an area of the brain called the internal globus pallidus (GPi). The GPi plays an integral role in the motor function and can be targeted with DBS to improve the symptoms of Parkinson's disease not adequately controlled by medication.
- Thomson Reuters StreetEvents
Edited Transcript of ABT earnings conference call or presentation 22-Jan-20 2:30pm GMT
Q4 2019 Abbott Laboratories Earnings Call
- Benzinga
The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories ...
- Investor's Business Daily
This Medical Giant Just Topped An Entry — Should You Buy ABT Stock Now?
ABT stock is one of the biggest diversified medical stocks behind Johnson & Johnson and Roche. As it aims for clearance of its Freestyle Libre 2 system, is it time to buy Abbott stock?
- Schaeffer's Investment Research
ABT Options Traders Pour In as Stock Hits New High
ABT call open interest is only in the 6th annual percentile
- American City Business Journals
This local regenerative medicine company is plotting its IPO
The commercial-stage business, which makes human tissue products, wants to begin trading publicly this year.
- Yahoo Finance
Health stocks reverse coronavirus gains as one analyst says the market is overreacting
Virus originating in Wuhan, China affected stock markets Tuesday, but one analyst said reactions were too strong.
- American City Business Journals
Abbott beats revenue projections as sales outperform previous year
The company posted full-year 2019 revenue of $31.9 billion, which was ahead of analyst projections and a 4.3% increase compared with 2018.
- Reuters
Abbott hits all-time high on quarterly revenue beat
JP Morgan analyst Robbie Marcus said he expected 2020 to be another year of "top-tier growth" for Abbott, driven by strength from its glucose monitoring device, FreeStyle Libre, and its pipeline of heart devices. Abbott's Chief Operating Officer Robert Ford, a key person behind Libre's growth, will replace long-time Chief Executive Miles White in March and is expected to prioritize sales of the glucose monitoring device and heart device MitraClip.
- Reuters
Incoming Abbott CEO says not looking to do any deals
Abbott Laboratories' incoming Chief Executive Officer Robert Ford said on Wednesday that deal-making was not on the company's agenda. "On the M&A side, we're not looking to do any deals right now," Ford, who currently serves as chief operating officer, said on a conference call. Ford also noted that Abbott intended to raise dividend payments to shareholders.
- Zacks
Chicago Econ Numbers & More Q4 Earnings: JNJ, ABT, FITB
Certain weeks of the year are rife with important information for the stock market. This is not one of those weeks.
- Zacks
Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark
We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.
- Investor's Business Daily
Health Giant Abbott Labs Beats Fourth-Quarter Sales Views And Rises In Buy Zone
ABT stock rose higher in a buy zone Wednesday after the medical technology company beat Wall Street's fourth-quarter revenue expectations and issued strong 2020 sales guidance.
- Zacks
Abbott (ABT) Meets Q4 Earnings Estimates
Abbott (ABT) delivered earnings and revenue surprises of 0.00% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- MarketWatch
Shares of Abbott Labs are up 1%; sales are up 7%
Shares of Abbott Laboratories were up 1% after the company reported sales increases across each of its four businesses in the fourth quarter of 2019. Net earnings were $1.05 billion, or 59 cents per share, in the fourth quarter, up from $654 million, or 37 cents per share, in the same quarter a year ago. Abbott said that adjusted earnings per share were $0.95 per share, compared with the FactSet consensus of $0.95. Total sales were up 7.1% to $8.3 billion, compared with the FactSet consensus of $8.2 billion. Medical device sales increased 9.7%, nutrition sales rose 5.2%, pharmaceutical sales were up 7.8%, and laboratory diagnostics sales rose by 8.4%. Sales of the company's MitraClip device, which is used in minimally invasive cardiovascular procedures, jumped 27% to $191 million. Abbott said it expects adjusted EPS of $3.55 to $3.65 in 2020. The FactSet consensus is $3.61. Abbott's stock has gained 25% over the last year. The SPDR Health Care Select Sector exchange-traded fund is up 16%, while the Dow Jones Industrial Average has gained about 18%.
- TheStreet.com
Dow Trades Higher as IBM Jumps, S&P 500 and Nasdaq Set Record Highs
Stocks rise as China moves swiftly to limit the spread of the deadly coronavirus. IBM lifts the Dow after an earnings beat.
- TheStreet.com
Abbott Labs Hits Mark on Fourth-Quarter Earnings, Boosts Guidance
Abbott Laboratories posts fourth-quarter earnings and sales in line with Wall Street forecasts, and lifts guidance.
- Investing.com
Abbott Labs Earnings inline, Revenue Beats In Q4
Investing.com - Abbott Labs reported on Wednesday fourth quarter earnings that matched analysts' forecasts and revenue that topped expectations.
- Benzinga
Q4 Earnings Preview: Abbott Laboratories
On Wednesday, January 22, Abbott Laboratories (NYSE: ABT ) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. Earnings and Revenue Wall Street analysts see Abbott ...
- TheStreet.com
Abbott Laboratories Could Climb to the $107 Area Next
Barring a negative surprise I would look for higher highs to be established in the days and weeks ahead.
- Benzinga
The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings
Biotech news flow remained light last week, although there were some notable developments such as FDA panel reviews of opioid pain drugs, a few clinical data readouts, presentations and updates at the ...
- Zacks
Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
- Barrons.com
How Alibaba and Tencent Brought Mobile Payments to Chinese New Year
Seven years ago, the two big China tech giants introduced mobile payments for the exchange of cash gifts—so-called red envelopes. Now the pair continue to compete to increase and engage users.
